Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Contrast-induced Nephropathy Clear all
Completed No phase listed Observational

Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography

NCT02263820
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Kidney Diseases
Interventions
Not listed
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jun 10, 2026, 10:00 AM EDT
Active, not recruiting Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Individual
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 2 Interventional

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

NCT01146925
View directory record Official record
Conditions
Contrast-Induced Acute Kidney Injury
Interventions
CRMD-001-Deferiprone, Placebo
Drug
Lead sponsor
CorMedix
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization

NCT04266834
View directory record Official record
Conditions
AKI, Contrast-induced Nephropathy
Interventions
Experimental Arm
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jun 10, 2026, 10:00 AM EDT
Terminated Phase 4 Interventional

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

NCT00476619
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
erythropoeitin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2009 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Not applicable Interventional

Remote Ischemic Preconditioning for Renal Protection in TAVI

NCT03347032
View directory record Official record
Conditions
Aortic Valve Stenosis, Renal Insufficiency, Contrast-induced Nephropathy
Interventions
Remote ischemic preconditioning, Control
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jun 10, 2026, 10:00 AM EDT
Completed No phase listed Observational

Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization

NCT03305874
View directory record Official record
Conditions
Contrast-induced Nephropathy
Interventions
Exposure to CBCIN risk score
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 4 Interventional Results available

Contrast Nephropathy and Nitrates

NCT01999517
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Intravenous Nitroglycerin, IV Fluids
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

NCT01252810
View directory record Official record
Conditions
Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
Interventions
GE-145
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
65 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment Undergoing CT

NCT00292487
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
Iopamidol 370 mgI/mL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Jun 10, 2026, 10:00 AM EDT
Completed No phase listed Observational

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847
View directory record Official record
Conditions
Acute Kidney Injury, Contrast-induced Nephropathy
Interventions
RENISCHEM L-FABP POC Test
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Chandler, Arizona • Concord, California • Clearwater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 10:00 AM EDT
Terminated Phase 1 Interventional

Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure

NCT00575419
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
N-acetylcysteine
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CXA-10 in Healthy Volunteers

NCT02127190
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10 emulsion, Placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jun 10, 2026, 10:00 AM EDT
Completed No phase listed Observational

Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI

NCT05132062
View directory record Official record
Conditions
Contrast-induced Nephropathy
Interventions
Percutaneous Coronary Intervention
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
14,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jun 10, 2026, 10:00 AM EDT
Not listed No phase listed Observational

DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry

NCT03825094
View directory record Official record
Conditions
Patients at Risk for Developing Contrast-induced Nephropathy
Interventions
DyeVert™ Contrast Reduction Systems
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Hartford, Connecticut • Hialeah, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Jun 10, 2026, 10:00 AM EDT
Completed No phase listed Observational

The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases

NCT00842868
View directory record Official record
Conditions
Atherosclerosis, Contrast Induced Nephropathy, Renal Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 2 Interventional

Contrast Enhanced Ultrasound for Renal Obstruction

NCT05090800
View directory record Official record
Conditions
Kidney; Obstruction, Renal Obstruction
Interventions
Definity contrast during ultrasound
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 10, 2026, 10:00 AM EDT
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Jun 10, 2026, 10:00 AM EDT
Not listed Phase 4 Interventional

Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy

NCT00939913
View directory record Official record
Conditions
Nephropathy
Interventions
intravenous NAC, Placebo
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Jun 10, 2026, 10:00 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

NCT00793182
View directory record Official record
Conditions
Renal Impairment
Interventions
Ioversol 320 mgI/mL, Iodixanol 320 mgI/mL
Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Tucson, Arizona • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 3 Interventional

Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate

NCT00312117
View directory record Official record
Conditions
Contrast Induced Nephropathy, Kidney Diseases
Interventions
Sodium bicarbonate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Jun 10, 2026, 10:00 AM EDT
Withdrawn Phase 4 Interventional

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions
Iodixanol, Ioversol, Iopromide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Not applicable Interventional Results available

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

NCT01976299
View directory record Official record
Conditions
Contrast Induced Nephropathy (CIN)
Interventions
AVERT
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jun 10, 2026, 10:00 AM EDT
Completed Phase 4 Interventional

Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)

NCT00289614
View directory record Official record
Conditions
Kidney Diseases
Interventions
Iopamidol 370 mgI/dL
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2008 · Synced Jun 10, 2026, 10:00 AM EDT